Misha V. Blagosklonny graduated with an MD and PhD from First Pavlov State Medical
University of St. Petersburg, RUS. Dr. Misha V. Blagosklonny subsequently
Immigrated to the USA, where he was
Awarded the prestigious Fogarty Fellowship from the National Institutes of Health.
Within the period of his fellowship in Leonard Neckers’ laboratory at the National
Cancer Institute (NCI), he was a co-author of 18 publications on
Diversified biomedical topics, suchas targeting
HSP90, p53, Bcl2, Erb2, and Raf-1. He also was the last writer for a clinical phase I/II
Trial article.
 
After authoring seven papers during a brief yet resulting
Senior research fellowship in the El-Deiry Cancer Research Lab at the University of Pennsylvania,
Dr. Blagosklonny returned to NCI to team up with Tito Fojo. Together, they
Published 26 papers. In addition, Dr. Mikhail Blagosklonny published a
Lot of experimental research articles and theoretical articles as lead
Author. Those sole-author publications
Discussed two crucial topics.
The first of those explained selectively killing cancer
Cells with deregulated cell cycle or drug resistance via
Confirming their resistance. The results and underlying
Notion were so revolutionary that they were inadequately cited by
Other scientists as “reversal of resistance, ” even though the paper was
Titled, “Exploiting of drug resistance instead of its reversal. ” One major
Supporter of this concept was the world-famous scientist Arthur Pardee, with whom Dr.
Blagosklonny co-authored a joint paper in 2001.
 
The second theme throughout Dr. Blagosklonny’s sole-author publications
Is a research method to come up with knowledge via
Bringing several facts together from seemingly irrelevant fields.
This results in new notions containing testable forecasts, which in
Turn can be “tested” by analyzing the literature further. Once again, the
Concept was co-authored by Arthur Pardee in a 2002 article in Nature. The
First success of the new research method was the description of the feedback
Regulation of p53, as confirmed by the discovery of mdm2/p53 loop; and the
Explanation why mutant p53 is always overexpressed, published in 1997. The most
Significant outcome discovered by Dr.Blagosklonny’s research methods is the hyperfunction (or quasi-programmed)
Theory of aging and the revelation of rapamycin as an exceptionally well-tolerated
Anti-aging drug, published in 2006. As mentioned in Scientific American,
Michael Hall, who discovered mTOR in 1991, gives Dr. Blagosklonny credit for
“connecting dots that others don' t even see. ”
 
In 2002, Dr. Blagosklonny became associate professor of medicine at New York Medical College.
He decided to accept responsibilities as a senior scientist at Ordway
Research Institute in Albany, New York, in 2005, prior to receiving another
Position at Roswell Park Cancer Institute as professor of oncology in 2009.
 
Since joining Roswell Park Comprehensive Cancer Center in 2009, Dr. Blagosklonny
Has studied the prevention of cancer (an age-related disease) by
Stopping body aging — in other words, “preventing cancer
Via staying young. ” His laboratory closely worked together with
Andrei Gudkov’s and conducted research on the suppression of
Cellular senescence, namely suppression of cellular conversion from healthy quiescence to
Permanent senescence. This resulted in the discovery of extra anti-aging
Medicines beyond rapamycin. The cell culture studies were
Complemented by studies in mice, including several models such as
Standard and aging mice, p53-deficient mice, and mice on a high-fat diet.
 
Dr. Mikhail Blagosklonny has also published extensively on the prevention of cellular
Senescence by rapamycin and other mTOR inhibitors, life
Extension and cancer stoppage in mice, and combinations of anti-
Aging medicines to be taken by humans. A
Rapamycin-based combination of seven clinically available drugs has
Been named the “Koschei Formula” and is now used for the treatment of aging in patients
At the Alan Green Clinic in Little Neck, New York.

https://www.crunchbase.com/person/mikhail-blagosklonny#section-overview
https://www.feverlab.net/pages/publicationpdfs/2014T_AAR%20New%20research%20journals.pdf
https://tandfonline.com/doi/abs/10.4161/cbt.8.9.8899